Bivalirudin as a foundation anticoagulant in peripheral vascular disease: A safe and feasible alternative for renal and iliac interventions

Journal of Invasive Cardiology

Volumn 15, Issue 6, 2003, Pages 334-342

  Allie, David E ^a   Lirtzman, Mitchell D ^a   Wyatt, Charles H ^a   Keller, V Antoine ^a   Khan, Mohamed H ^a   Khan, Muhammad A ^a   Fail, Peter S ^a   Hebert, Chris J ^a   Ellis, Sonja D ^a   Mitran, Elena ^a   Chaisson, Gary ^a   Stagg Jr , Samuel ^a   Allie, Adam A ^a   Walker, Craig M ^a  

^a NONE

Author keywords

Anticoagulation; Peripheral intervention; Peripheral vascular disease

Indexed keywords

ANTICOAGULANT AGENT; HEPARIN; HIRULOG;

ADULT; AGED; ANTICOAGULATION; ARTICLE; BLEEDING; BRAIN HEMORRHAGE; CONTROLLED STUDY; DRUG SAFETY; ECHOGRAPHY; FEASIBILITY STUDY; FEMALE; FOLLOW UP; HOSPITALIZATION; HUMAN; ILIAC ARTERY; ISCHEMIA; MAJOR CLINICAL STUDY; MALE; MOBILIZATION; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PERIPHERAL VASCULAR DISEASE; RENAL ARTERY; SIDE EFFECT; THROMBOCYTOPENIA; THROMBOSIS; TREATMENT OUTCOME; VASCULAR ACCESS;

AGED; ANTICOAGULANTS; ARTERIAL OCCLUSIVE DISEASES; CASE-CONTROL STUDIES; COHORT STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HEPARIN, LOW-MOLECULAR-WEIGHT; HIRUDINS; HUMANS; ILIAC ARTERY; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; PERIPHERAL VASCULAR DISEASES; RECOMBINANT PROTEINS; RENAL ARTERY OBSTRUCTION; RETROSPECTIVE STUDIES; RISK ASSESSMENT; TREATMENT OUTCOME; VASCULAR PATENCY;

EID: 0037837361     PISSN: 10423931     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (46)

1. Krajcer Z, Howell MH. Update on endovascular treatment of peripheral vascular disease: New tools, techniques and indications. Tex Heart Inst J 2000;27:369-385.
2. Becker GJ, McClenny TE, Kovacs ME, et al. The importance of increasing public awareness of peripheral artery disease. J Vasc Interv Radiol 2002;13:7-11.
3. Gruentzig AR, Senning A, Siegenthaler WE. Nonoperative dilation of coronary artery stenosis. N Engl J Med 1979;301:61-68.
4. Aguirre FV, Gill JB. Increasing benefit, reducing risk: Focusing on hemorrhagic complications in percutaneous coronary intervention. J Invas Cardiol 2002;14:48B-54B.
5. The CAPTURE Investigators. Randomized placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: The CAPTURE study. Lancet 1997;349:1429-1435.
6. Topol EJ, Molitemo D, Herrman H, et al. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization. N Engl J Med 2001;344:1888-1894.
7. Bittl JA, Chaitman B, Feit F, et al. Bivalirudin versus heparin during coronary angioplasty for unstable or post-infarction angina: The final reanalysis of the bivalirudin angioplasty study. Am Heart J 2001;142:952-959.
8. Ouriel K. Peripheral arterial disease. Lancet 2001;358:1257-1264.
9. Hirsh J, Warkentin TE, Raschke R, et al. Heparin and low molecular weight heparin: Mechanisms of action, pharmacokinetics, dosing considerations, monitoring, efficacy and safety. Chest 1998;114:489S-510S.
10. Linhardt RJ, Gunay NS. Production and chemical processing of low molecular weight heparins. Semin Thromb Hemostasis 1999;25(Suppl 3):5-16.
11. Lincoff AM, Bittl JA, Harrington RA, et al., for the REPLACE-2 Investigators. Bivalirudin and provisional GP IIb/IIIa blockade compared with heparin and planned GP IIb/IIIa blockade during percutaneous coronary angioplasty. JAMA 2003;289:853-863.
12. Weitz JI, Bates SM. Acute coronary syndromes: A focus on thrombin. J Invas Cardiol 2002;14(Suppl B):2B-7B.
13. Lewis BE. Thrombocytopenia and outcomes in invasive cardiology. J Invas Cardiol 2002;14(Suppl B):38B-47B.
14. Bates SM, Weitz JI. Direct thrombin inhibitors for treatment of arterial thrombosis: Potential differences between bivalirudin and hirudin. Am J Cardiol 1998;82:12P-18P.
15. Semba CP, Murphy TP, Bakal CW. Thrombolytic therapy with use of alteplase (rt-PA) in peripheral arterial occlusive disease: Review of the clinical literature. J Vasc Interv Radiol 2000;11:149-161.
16. Campbell KR, Mahaffrey KW, Lewis BE, et al. Bivalirudin in patients with heparin-induced thrombocytopenia undergoing percutaneous coronary intervention. J Invas Cardiol 2000;12:14F-19F.
17. Warkentin TE. Clinical presentation of heparin-induced thrombocytopenia. Semin Hematology 1998;35(Suppl 5):9-16.
18. Kelton JG. The clinical management of heparin-induced thrombocytopenia. Semin Hematology 1999;36(Suppl 1):17-21.
19. Warkentin TE. Heparin-induced thrombocytopenia: Pathogenesis, frequency, avoidance and management. Drug Safety 197;5:325-341.
20. Warkentin TE, Kelton JG. A 14-year study of heparin-induced thrombocytopenia. Am J Med 1996;101:502-507.
21. Visentin GP, Malik M, Cyganiak KA, Aster. Patients treated with unfractionated heparin during open heart surgery are at high risk to form antibodies reactive with heparin: Platelet factor 4 complexes. J Lab Clin Med 1996;128:376-383.
22. Mattoili AV, Bonetti L, Stemieri S, Mattioli G. Heparin-induced thrombocytopenia in patients treated with unfractionated heparin: Prevalence ofthrombosis in 1 year follow-up. Ital Heart J 2000;1:39-42.
23. Lincoff AM, Kleiman NS, Kottke-Marchant K, et al. Bivalirudin with planned or provisional abciximab versus low-dose heparin and abciximab during percutaneous coronary revascularization: Results of the Comparison of Abciximab Complications with Hirulog for Ischemic Events Trial (CACHET). Am Heart J 2002;143:847-853.
24. Lincoff AM. Pilot study of bivalirudin versus heparin during percutaneous coronary intervention with stenting and GP IIb/IIIa blockade: Results of the REPLACE-1 trial (Abstr). J Am Coll Cardiol 2002;39(Suppl A):16A.
25. Robson R, White H, Aylward P, Frampton C. Bivalirudin pharmacokinetics and pharmacodynamics: Effect of renal function, dose and gender. Clin Pharmacol Ther 2002;71:433-439.
26. Robson R. The use of bivalirudin in patients with renal impairment. J Invas Cardiol 2000;12(Suppl F):33F-36F.
27. Lui HK. Dosage, pharmacological effects and clinical outcomes for bivalirudin in percutaneous coronary intervention. J Invas Cardiol 2000;12:41F-52F.
28. Topol EJ, Bonan R, Jewitt D, et al. Use of direct thrombin inhibitor, hirulog, in place of heparin during coronary angioplasty. Circulation 1993;87:1622-1629.
29. Stewart WJ, McSweeney SM, Kellett MA, et al. Increased risk of severe protamine reactions in NPH insulin-dependent diabetic undergoing cardiac catheterization. Circulation 1984;70:788-792.
30. Vincent GM, Janowski M, Menlove R. Protamine allergy reactions during cardiac catheterization and cardiac surgery: Risk in patients taking protamine-insulin preparation. Cathet Cardiovasc Diagn 1987;13:214-217.
31. Aguirre FV, Topol EJ, Ferguson JJ, et al. Bleeding complications with the chimeric antibody to platelet glycoprotein IIb/IIIa integrin in patients undergoing percutaneous coronary intervention. The EPIC Investigators. Circulation 1995;91:2882-2890.
32. Ellis SG. Elective coronary angioplasty: Techniques and complications. In: Topol E (ed). Textbook of Interventional Cardiology. WB Saunders: Philadelphia, 1999: pp. 147-162.
33. Lincoff AM, Topol E. Abrupt vessel closure. In: Topol E (ed). Textbook of Interventional Cardiology. WB Saunders: Philadelphia, 1999: pp. 163-187.
34. Best P, Lennon R, Ting H, et al. Even mild renal insufficiency is associated with increased mortality after percutaneous coronary intervention. J Am Coll Cardiol 2001;37:76A.
35. Capek P, McLean GK, Berkowitz HD. Femoropopliteal angioplasty. Factors influencing long-term success. Circulation 1991;83(Suppl 2):170-180.
36. Hunink MRM, Magruder CD, Meyerovitz MR, et al. Risks and benefits of femoropopliteal percutaneous balloon angioplasty. J Vasc Surg 1993;17:183-194.
37. Ouriel K, Shortell CK, DeWeese JA, et al. A comparison of thrombolytic therapy with operative revascularization in the initial treatment of acute peripheral arterial ischemia. J Vasc Surg 1994;19:1021-1030.
38. Ouriel K. Surgery versus thrombolyitc therapy in the management of peripheral arterial occlusions. J Vasc Interv Radiol 1995;6:48S-54S.
39. Miller JM, Ohman EM, Moliterno DJ, et al. Restenosis: The clinical issues. In: Topol E (ed). Textbook of Interventional Cardiology. WB Saunders: Philadelphia, 1999: pp. 379-415.
40. Henry TD. Overcoming heparin limitations in high-risk percutaneous coronary intervention: The alternative strategy - Replacing heparin with bivalirudin. J Invas Cardiol 2002;14:19B-26B.
41. Rosenfield K, Schainfeld RS, Isnor JM. Percutaneous revascularization in peripheral arterial disease. Current Prob Cardiol 1996;31:1-96.
42. Asinger RW, Henry HD, Herzog CA, et al. Clinical outcomes of PTCA in chronic renal failure: A case-control study for comorbid features and evaluation of dialysis dependence. J Invas Cardiol 2001;13:21-28.
43. Gray BH, Sullivan TM, Childs MB, et al. High incidence of restenosis/reocclusion of stents in the percutaneous treatment of long segment superficial femoral artery disease after suboptimal angioplasty. J Vasc Surg 1997;25:74-83.
44. Ouriel K, Shortell CK, Azodo MVU, et al. Acute peripheral vascular occlusion: Predictors of success in catheter-directed thrombolytic therapy. Radiology 1994;193:561-566.
45. Ouriel K, Veith FJ, Sarahara AA. A comparison of recombinant urokinase with vascular surgery as initial treatment for acute arterial occlusion of the legs. N Engl J Med 1998;338:1105-1111.
46. Xiao Z, Theroux P. Platelet activation with unfractionated heparin at therapeutic concentrations and comparisons with a low molecular weight heparin and with a direct thrombin inhibitor. Circulation 1998;97:251-256